Table 1

Baseline characteristics of participants by syphilis stage and initial versus repeat syphilis presentation (prospective study)

ControlInitial primary/secondary syphilisReinfection primary/secondary syphilisp Value*Initial latent syphilisReinfection latent syphilis p Value*
N=3025291126
Men30 (100)24 (96)30 (100)0.27711 (100)26 (100)1
Age (years)37 (32–45)34 (30–49)41 (31–50)0.34234 (30–49)41 (39–47)0.321
MSM (of men)24 (80)24 (100)29 (100)0.27710 (90.9)26 (100)0.119
HIV-infected30 (100)17 (68.0)27 (93.1)0.01810 (90.9)25 (96.2)0.519
CD4+ T-cell count (cells/μL)577 (392–684)646 (483–836)636 (448–774)0.788540 (368–768)595 (487–693)0.611
HIV viral load (copies per mL)34 (10–814)10 (10–10)10 (10–36)0.35934 (10–141 000)10 (10–10)**0.023
On ART (of HIV infected)24 (80)15 (88.2)24 (88.9)0.9476 (60.0)25 (100)*0.001
Syphilis treatment
 Benzathine-penicillin GNA25 (100)29 (100)111 (100)24 (92.3)0.314
 DoxycyclineNA0 (0)0 (0)10 (0)2 (7.7)0.344
Other STIs0 (30)0 (0)1 (3.3)0.3670 (0)3 (12)0.211
No. of sex partners prior 12 months1.5 (1–6)6.5 (2–14.5)9 (4–31)0.2645.5 (0.5–9.5)8.0 (3–13)0.122
  • Data are n (%), median (IQR), unless otherwise stated.

  • *p Value is for comparison between initial and repeat syphilis groups.

  • †p Values in this column are for comparison with the control group and are denoted as follows: *p<0.05, **p<0.005, ***p<0.0005.

  • ART, antiretroviral therapy; MSM, men who have sex with men; NA, not applicable.